Furiex Pharmaceuticals, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation of Acquisition by Forest Laboratories, Inc.

April 29, 2014

Bernstein Liebhard LLP is investigating whether the Board of Directors of Furiex Pharmaceuticals, Inc. (“Furiex” or the “Company”) (NASDAQ: FURX) breached its fiduciary duty to its shareholders in agreeing to sell Furiex to Forest Laboratories, Inc.

Under the terms of the agreement, Furiex shareholders will receive $95.00 in cash plus a Contingent Value Right worth up to $30.00 for each share they own.  The investigation is focused on the potential unfairness of the price to Furiex shareholders and the process by which the Furiex Board of Directors considered and approved the transaction.

If you are interested in discussing your rights as a Furiex stockholder, with no obligation or cost to you, please contact U. Seth Ottensoser at (877) 779-1414 or Ottensoser@bernlieb.com.

Bernstein Liebhard LLP has pursued hundreds of securities, consumer and shareholder rights cases and recovered over $3 billion for its clients.  It has been named to The National Law Journal’s “Plaintiffs’ Hot List” in each of the last twelve years.